Showing results (51-60 of 168) with videos related to
Sort By:
Pageof 17
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 1, 1988
Optimum processing protocols for volume determination of the liver and spleen from SPECT imaging with technetium-99m sulfur colloidF Mut, S Glickman, D Marciano, et al.Nucleic Acids Research|December 1, 2016
Division of labor among Mycobacterium smegmatis RNase H enzymes: RNase H1 activity of RnhA or RnhC is essential for growth whereas RnhB and RnhA guard against killing by hydrogen peroxide in stationary phaseRicha Gupta, Debashree Chatterjee, Michael S Glickman, et al.The Journal of Biological Chemistry|November 28, 2000
The Mycobacterium tuberculosis cmaA2 gene encodes a mycolic acid trans-cyclopropane synthetaseM S Glickman, S M Cahill, W R JacobsNature Reviews. Urology|February 5, 2014
The mechanism of action of BCG therapy for bladder cancer--a current perspectiveGil Redelman-Sidi, Michael S Glickman, Bernard H BochnerCompendium of Continuing Education in Dentistry (Jamesburg, N.J. : 1995)|March 6, 2023
Esthetic Considerations In Minimally Invasive Orthognathic SurgerySung Hoon Choo, Robert S Glickman, Thomas G WiedemannCompendium of Continuing Education in Dentistry (Jamesburg, N.J. : 1995)|February 21, 2023
Graftless Implantology as a Forward-Looking Clinical Concept for Highly Atrophic Maxillary ArchesSung Hoon Choo, Robert S Glickman, Thomas G WiedemannJournal of Bacteriology|May 18, 2010
Redundant function of cmaA2 and mmaA2 in Mycobacterium tuberculosis cis cyclopropanation of oxygenated mycolatesDaniel Barkan, Vivek Rao, George D Sukenick, et al.The Journal of Experimental Medicine|February 16, 2005
Mycobacterium tuberculosis controls host innate immune activation through cyclopropane modification of a glycolipid effector moleculeVivek Rao, Nagatoshi Fujiwara, Steven A Porcelli, et al.Mbio|September 20, 2018
The Microbiome and Tuberculosis: Early Evidence for Cross TalkSivaranjani Namasivayam, Alan Sher, Michael S Glickman, et al.Infection Control and Hospital Epidemiology|February 16, 2019
Viral oncolytic immunotherapy in the war on cancer: Infection control considerationsElizabeth V Robilotti, Asmita Kumar, Michael S Glickman, et al.Pageof 17